Shanghai Junshi Biosciences Co., Ltd. (SHA:688180)

China flag China · Delayed Price · Currency is CNY
34.00
+0.06 (0.18%)
Feb 27, 2026, 3:00 PM CST
Market Cap30.59B +36.3%
Revenue (ttm)2.48B +38.9%
Net Income-949.86M
EPS-0.96
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume6,280,787
Average Volume13,643,048
Open33.60
Previous Close33.94
Day's Range33.55 - 34.12
52-Week Range25.60 - 51.40
Beta0.79
RSI40.33
Earnings DateMar 14, 2026

About SHA:688180

Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of malignant tumors, neurological, autoimmune, chronic metabolic, nervous system, and infectious diseases in the People's Republic of China. The company was founded in 2012 and is headquartered in Shanghai, People's Republic of China. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 2,578
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688180
Full Company Profile

Financial Performance

In 2024, SHA:688180's revenue was 1.95 billion, an increase of 29.67% compared to the previous year's 1.50 billion. Losses were -1.28 billion, -43.90% less than in 2023.

Financial Statements

News

Junshi Biosciences Announces Acceptance of the NDA for Roconkibart (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis

SHANGHAI, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the d...

2 months ago - GlobeNewsWire

Junshi Biosciences Announces Primary Endpoints Met in JS001sc's Phase 3 Study for the 1ST-line Treatment of NSQ-NSCLC

SHANGHAI, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the d...

3 months ago - GlobeNewsWire

Junshi Biosciences Announces FDA's Approval of IND Application for Phase 2/3 Clinical Study of JS207 for the Neoadjuvant Treatment of NSCLC Patients

SHANGHAI, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the d...

4 months ago - GlobeNewsWire

Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints

JS005 has achieved positive results in a multi-center, randomized, double-blind, parallel, placebo-controlled pivotal registrational Phase 3 clinical study

6 months ago - GlobeNewsWire

TREOS Bio Partners with Charité Berlin and Junshi Biosciences to Launch Pivotal Phase II Clinical Trial in Refractory MSS Colorectal Cancer

Bridge financing of $2.1 million supports initiation of pivotal Phase II study in 140 patients with microsatellite stable metastatic colorectal cancer, addressing 85% of CRC cases with limited treatme...

6 months ago - GlobeNewsWire

Junshi Biosciences Announces 2025 Interim Financial Results and Provides Corporate Updates

SHANGHAI, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the...

6 months ago - GlobeNewsWire